Semax
Overview
Semax is a synthetic peptide derived from an ACTH fragment and developed in Russia for neurological research. Unlike stimulants, it is being investigated for its effects on brain-derived neurotrophic factor (BDNF), learning, memory, attention, and neuroprotection. Researchers believe Semax may enhance communication between neurons, reduce oxidative stress, and support recovery following neurological injury. Human studies have explored stroke recovery, cognitive impairment, and attention disorders, while laboratory research continues to examine its effects on inflammation and neurotransmitter regulation. Most research uses intranasal administration because it allows rapid delivery to the central nervous system. Reported adverse effects are generally mild and include nasal irritation, headache, or temporary stimulation. Although early research is promising, larger international clinical trials are needed before broad conclusions can be made. Semax remains an investigational neuropeptide in many countries and should be viewed as an area of active research rather than an established treatment.
Research Reminder
This overview is educational and summarizes current research. Many discussed applications remain investigational, and evidence quality varies by condition.